Zacks: NuCana PLC (NCNA) Given Consensus Rating of “Strong Buy” by Analysts

Shares of NuCana PLC (NASDAQ:NCNA) have earned an average broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.

Brokerages have set a 12 month consensus price target of $26.50 for the company and are forecasting that the company will post ($0.14) EPS for the current quarter, according to Zacks. Zacks has also assigned NuCana an industry rank of 185 out of 265 based on the ratings given to its competitors.

How to Become a New Pot Stock Millionaire

Separately, Zacks Investment Research downgraded NuCana from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th.

Shares of NuCana stock traded up $0.26 on Monday, reaching $17.69. The company had a trading volume of 45,670 shares, compared to its average volume of 117,846. NuCana has a 52-week low of $9.32 and a 52-week high of $29.75.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Sofinnova Management VIII L.L.C. boosted its holdings in NuCana by 600.0% in the fourth quarter. Sofinnova Management VIII L.L.C. now owns 4,666,666 shares of the company’s stock valued at $47,180,000 after purchasing an additional 4,000,000 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in NuCana by 40.1% in the fourth quarter. Alliancebernstein L.P. now owns 910,358 shares of the company’s stock valued at $9,204,000 after purchasing an additional 260,358 shares in the last quarter. UBS Asset Management Americas Inc. boosted its holdings in NuCana by 4.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 464,600 shares of the company’s stock valued at $4,697,000 after purchasing an additional 19,800 shares in the last quarter. Alps Advisors Inc. acquired a new position in NuCana in the fourth quarter valued at approximately $357,000. Finally, Perceptive Advisors LLC acquired a new position in NuCana in the third quarter valued at approximately $3,674,000. 30.70% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Zacks: NuCana PLC (NCNA) Given Consensus Rating of “Strong Buy” by Analysts” was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3297599/zacks-nucana-plc-ncna-given-consensus-rating-of-strong-buy-by-analysts.html.

NuCana Company Profile

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Get a free copy of the Zacks research report on NuCana (NCNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Mimecast  Receiving Somewhat Favorable Media Coverage, Report Finds
Mimecast Receiving Somewhat Favorable Media Coverage, Report Finds
Descartes Systems Group  Earning Positive News Coverage, Accern Reports
Descartes Systems Group Earning Positive News Coverage, Accern Reports
Insider Selling: Intuitive Surgical  EVP Sells 2,770 Shares of Stock
Insider Selling: Intuitive Surgical EVP Sells 2,770 Shares of Stock
Mark Sachleben Sells 7,500 Shares of New Relic  Stock
Mark Sachleben Sells 7,500 Shares of New Relic Stock
Home BancShares  Chairman John W. Allison Purchases 20,000 Shares
Home BancShares Chairman John W. Allison Purchases 20,000 Shares
Luminex Co.  Expected to Announce Quarterly Sales of $80.40 Million
Luminex Co. Expected to Announce Quarterly Sales of $80.40 Million


© 2006-2018 Ticker Report. Google+.